Blair William & Co. IL Buys 213 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Posted by Defense World Staff on May 28th, 2023

Blair William & Co. IL grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 4.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,104 shares of the medical research company’s stock after purchasing an additional 213 shares during the quarter. Blair William & Co. IL’s holdings in Charles River Laboratories International were worth $1,112,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Charles River Laboratories International by 417.3% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,288 shares of the medical research company’s stock worth $253,000 after buying an additional 1,039 shares in the last quarter. Belpointe Asset Management LLC grew its holdings in Charles River Laboratories International by 8.7% in the fourth quarter. Belpointe Asset Management LLC now owns 1,178 shares of the medical research company’s stock worth $257,000 after purchasing an additional 94 shares during the period. CIBC Private Wealth Group LLC raised its holdings in shares of Charles River Laboratories International by 1.5% during the third quarter. CIBC Private Wealth Group LLC now owns 103,472 shares of the medical research company’s stock valued at $20,364,000 after purchasing an additional 1,539 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Charles River Laboratories International by 6.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,059 shares of the medical research company’s stock worth $2,767,000 after purchasing an additional 804 shares in the last quarter. Finally, Pallas Capital Advisors LLC grew its stake in shares of Charles River Laboratories International by 10.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 7,289 shares of the medical research company’s stock valued at $1,583,000 after buying an additional 672 shares during the period. Institutional investors and hedge funds own 97.80% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $190.39, for a total value of $65,684.55. Following the transaction, the executive vice president now owns 24,026 shares of the company’s stock, valued at $4,574,310.14. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Citigroup reduced their target price on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating for the company in a research note on Thursday, February 23rd. Credit Suisse Group reduced their target price on Charles River Laboratories International from $260.00 to $255.00 in a research note on Friday, May 12th. Deutsche Bank Aktiengesellschaft reduced their target price on Charles River Laboratories International from $260.00 to $250.00 in a research note on Friday, May 12th. Guggenheim upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $255.00 price target for the company in a research note on Thursday, February 23rd. Finally, TheStreet downgraded Charles River Laboratories International from a “b-” rating to a “c” rating in a research note on Thursday, May 11th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $260.73.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $194.12 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $181.22 and a twelve month high of $262.00. The stock’s 50 day moving average price is $195.98 and its 200-day moving average price is $217.96. The company has a market capitalization of $9.94 billion, a PE ratio of 20.07, a PEG ratio of 1.35 and a beta of 1.34. The company has a quick ratio of 1.21, a current ratio of 1.48 and a debt-to-equity ratio of 0.88.

Charles River Laboratories International (NYSE:CRL – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share for the quarter, topping the consensus estimate of $2.75 by $0.23. The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Charles River Laboratories International had a net margin of 12.13% and a return on equity of 20.12%. The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.49 earnings per share. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.28 EPS for the current year.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.